Filing Flows › Health Care › PetVivo Holdings (PETV)
PetVivo Holdings (PETV) earnings and revenue breakdown
Latest: Q1 FY27 · 10-Q filed Aug 14, 2026 · PetVivo Holdings (PETV) Q1 FY27 earnings results →
Q1 FY27 Revenue up 14% year over year to $338K · 478¢ of every $1 of revenue lost · operating margin -476.6%
PetVivo Holdings made $338K in Q1 FY27 (+14% Y/Y). Operating margin -476.6%, net loss $1.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $338K in Q1 FY27, up 13% year over year and up 33% from the previous quarter.
Gross margin was 66.2%, up 3.4 points from Q1 FY26. Operating costs exceeded revenue by $1.6M, an operating margin of -476.6%. Operating expenses fell 10% while revenue rose 13%. The quarter ended with a net loss of $1.6M, narrower than the previous quarter's $3.0M loss.
Operating cash flow was −$1.0M. Non-cash charges added back $135K of depreciation and amortization and $461K of share-based compensation. Working capital and other items added $53K. Capital expenditures of $12K exceeded it, leaving free cash flow of −$1.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 FY27 | 10-Q | Aug 14, 2026 | $338K | +14% | -476.6% | −$1.6M | −$966K |
| Q4 FY26 | 10-K | Jun 29, 2026 | $255K | +13% | n/m | −$3.0M | −$812K |
| Q3 FY26 | 10-Q | Feb 17, 2026 | $286K | -51% | -766.0% | −$2.2M | −$1.5M |
| Q2 FY26 | 10-Q | Nov 14, 2025 | $303K | +51% | -681.0% | −$3.0M | −$2.2M |
| Q1 FY26 | 10-Q | Aug 14, 2025 | $298K | +140% | -619.9% | −$2.3M | −$1.6M |
| Q4 FY25 | 10-K | Jul 10, 2025 | $225K | +366% | -925.4% | −$2.4M | −$1.2M |
| Q3 FY25 | 10-Q | Feb 14, 2025 | $583K | -2% | -301.5% | −$1.8M | −$961K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About PetVivo Holdings
PetVivo Holdings, Inc. (the “Company,” “PetVivo,” “we” or “us) is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of ten issued patents (consisting of six U.S. patents and four foreign patents), two U.S. patent applications, and six proprietary trade secrets protects the Company’s biomaterials, products, production processes and methods of use. The Company began commercialization of its lead product Spryng ® with OsteoCushion ® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses, in the second quarter of its fiscal year ended March 31, 2022.
In its own words, from its 10-K, filed Jun 29, 2026.
PetVivo Holdings against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +14% against the peers' median +5%. Operating margin: -476.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PETV PetVivo Holdings | Q1 FY27 | $338K | +14% | -476.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: PetVivo Holdings 10-Q on SEC EDGAR · CIK 1512922 · Surgical & Medical Instruments & Apparatus
More on PETV
History
Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results